06:47:32 Europe / Stockholm
Svenska | English

Nykode Therapeutics

Share price & Turnover

Share price change and turnover during the day of this press release

Calendar

2025-02-26 Year-end Report 2024
2024-11-27 Quarterly Report 2024-Q3
2024-08-21 Quarterly Report 2024-Q2
2024-05-21 Ex-date Ordinary Dividend NYKD 0.00 NOK
2024-05-16 Annual General meeting
2024-05-14 Quarterly Report 2024-Q1
2024-02-28 Year-end Report 2023
2023-11-15 Quarterly Report 2023-Q3
2023-08-23 Quarterly Report 2023-Q2
2023-05-16 Quarterly Report 2023-Q1
2023-05-12 Ex-date Ordinary Dividend NYKD 0.00 NOK
2023-05-11 Annual General meeting
2023-02-28 Year-end Report 2022
2022-11-23 Quarterly Report 2022-Q3
2022-08-24 Quarterly Report 2022-Q2
2022-05-16 Quarterly Report 2022-Q1
2022-05-13 Ex-date Ordinary Dividend NYKD 0.00 NOK
2022-05-12 Annual General meeting
2022-03-31 Year-end Report 2021
2021-12-22 Extra General Meeting 2021
2021-11-17 Quarterly Report 2021-Q3
2021-08-26 Quarterly Report 2021-Q2
2021-05-12 Quarterly Report 2021-Q1
2021-05-06 Ex-date Ordinary Dividend NYKD 0.00 NOK
2021-05-05 Annual General meeting
2021-04-21 Year-end Report 2020
2020-11-17 Quarterly Report 2020-Q3
2020-08-27 Quarterly Report 2020-Q2
2020-07-07 Split NYKD 1:5
2020-07-06 Extra General Meeting
2020-05-12 Quarterly Report 2020-Q1
2020-04-22 Extra General Meeting

Description

CountryNorway
ListOB Match
SectorHealth care
IndustryBiotechnology
Nykode Therapeutics är verksamma inom bioteknik. Bolaget är idag specialiserade inom forskning och utveckling av immunologiska terapier och vacciner. Lösningarna används huvudsakligen för behandling av patienter med cancersjukdomar samt övriga allvarliga hälsotillstånd som kräver långsiktig behandling. Störst verksamhet återfinns inom den europeiska marknaden.
Nykode Therapeutics - Share capital increase from exercise of warrants
2023-11-10 17:13:28 
Oslo, Norway, November 10, 2023 - As a consequence of exercise of 531,802
warrants in Nykode Therapeutics ASA with expiry date December 31, 2023, the
share capital of Nykode Therapeutics ASA has increased by NOK 5,318.02 from NOK
3,250,437.09 to NOK 3,255,755.11. The number of outstanding shares in the
company has increased by 531,802 from 325,043,709 to 325,575,511, each with a
par value of NOK 0.01. The warrants were exercised by employees, where 133,335
warrants were exercised at a subscription price of NOK 7.0 per share and 398,467
warrants were exercised at a subscription price of NOK 9.4 per share.
Source Oslo Børs
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

An email has been sent to the given address. To login please click "Login" in that email to verify your account

Companies

Press releases